Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

XENON PHARMACEUTICALS INC.

(XENE)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-06 pm EST
39.19 USD    0.00%
01/31RBC Lifts Price Target on Xenon Pharmaceuticals to $51 From $49 Amid Increased Confidence on Patents, Keeps Outperform Rating, Speculative Risk Qualifier
MT
01/09Transcript : Xenon Pharmaceuticals Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 07:30 AM
CI
01/09Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Wells Fargo Initiates Xenon Pharmaceuticals With Overweight Rating, Price Target is $50

11/28/2022 | 07:49am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
WELLS FARGO & COMPANY 0.21% 47.68 Delayed Quote.15.48%
XENON PHARMACEUTICALS INC. 0.00% 39.19 Delayed Quote.-0.61%
All news about XENON PHARMACEUTICALS INC.
01/31RBC Lifts Price Target on Xenon Pharmaceuticals to $51 From $49 Amid Increased Confiden..
MT
01/09Transcript : Xenon Pharmaceuticals Inc. Presents at 41st Annual J.P. Morgan H..
CI
01/09Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
GL
01/09Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
AQ
01/04Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
GL
01/04Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
AQ
2022Goldman Sachs Initiates Coverage on Xenon Pharmaceuticals With Buy Rating, $60 Price Ta..
MT
2022Cowen Starts Xenon Pharmaceuticals at Outperform
MT
2022Xenon Pharmaceuticals Inc. Presents at Bank of Amer..
CI
2022Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at th..
AQ
More news
Analyst Recommendations on XENON PHARMACEUTICALS INC.
More recommendations
Financials (USD)
Sales 2022 12,2 M - -
Net income 2022 -127 M - -
Net cash 2022 720 M - -
P/E ratio 2022 -18,9x
Yield 2022 -
Capitalization 2 451 M 2 451 M -
EV / Sales 2022 142x
EV / Sales 2023 227x
Nbr of Employees 151
Free-Float 94,9%
Chart XENON PHARMACEUTICALS INC.
Duration : Period :
Xenon Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XENON PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 39,19 $
Average target price 50,40 $
Spread / Average Target 28,6%
EPS Revisions
Managers and Directors
Ian C. Mortimer Chief Financial & Operating Officer
Sherry Aulin Chief Financial Officer
Simon Neil Pimstone Chairman
Sheila M. Grant Executive VP-Research & Development Operations
Christopher Kenney Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
XENON PHARMACEUTICALS INC.-0.61%2 451
REGENERON PHARMACEUTICALS, INC.8.54%83 397
VERTEX PHARMACEUTICALS4.24%78 258
WUXI APPTEC CO., LTD.12.89%39 435
BIONTECH SE-5.43%34 256
BEIGENE, LTD.11.48%25 531